Pharmaceuticals & Biotech/Lifesciences
FNArena Windows (Sectors)
Introduction to FNArena Windows
FNArena Windows offers subscribers the option to investigate ASX-listed stocks against their peers. FNArena developed its own sector methodology which in our view overcomes many flaws and disadvantages connected with GICS sectors. Our system starts with three broad sector labels: COMMODITIES, FINANCIAL SERVICES and INDUSTRIALS. From here onwards subscribers can explore further through gradually narrowing branches. This is not investment advice, but simply another window on the Australian Stock Exchange to provide better insight and to assist FNArena subscribers while conducting their own market analysis.
Latest Stories
Race Oncology tells a story all too familiar among developing Aussie biotechs, Tim Boreham reports
Apr 09 2024
GLP-1s offer far more across the healthcare sector than just weight-loss, with far-reaching societal implications, explains T. Rowe Price’s Nabil Hanano
Apr 03 2024
ASX CODE | COMPANY NAME | LAST PRICE | 52WK HIGH | 52WK LOW | P/E | CONSENSUS TARGET |
---|---|---|---|---|---|---|
ARX | AROA BIOSURGERY LIMITED | $0.50 | $1.09 | $0.48 |
$1.05 |
|
AVH | AVITA MEDICAL INC | $2.77 | $6.27 | $2.66 |
$5.10 |
|
CSL | CSL LIMITED | $278.45 | $312.99 | $228.65 | 29.7 |
$316.733 |
CUV | CLINUVEL PHARMACEUTICALS LIMITED | $14.99 | $21.53 | $12.96 | 21.6 |
$18.75 |
GSS | GENETIC SIGNATURES LIMITED | $0.68 | $0.75 | $0.38 |
$0.75 |
|
IMM | IMMUTEP LIMITED | $0.45 | $xx.xx | $xx.xx | xx.x | xx.xx |
IMU | IMMUTEP LIMITED | $0.08 | $xx.xx | $xx.xx | xx.x | xx.xx |
MAP | MICROBA LIFE SCIENCES LIMITED | $0.16 | $xx.xx | $xx.xx | xx.x | xx.xx |
MSB | MESOBLAST LIMITED | $0.92 | $xx.xx | $xx.xx | xx.x | xx.xx |
NEU | NEUREN PHARMACEUTICALS LIMITED | $18.85 | $xx.xx | $xx.xx | xx.x | xx.xx |
PAR | PARADIGM BIOPHARMACEUTICALS LIMITED | $0.29 | $xx.xx | $xx.xx | xx.x | xx.xx |
PBP | PROBIOTEC LIMITED | $2.84 | $xx.xx | $xx.xx | xx.x | xx.xx |
PER | PERCHERON THERAPEUTICS LIMITED | $0.06 | $xx.xx | $xx.xx | xx.x | xx.xx |
PNV | POLYNOVO LIMITED | $2.09 | $xx.xx | $xx.xx | xx.x | xx.xx |
TLX | TELIX PHARMACEUTICALS LIMITED | $14.88 | $xx.xx | $xx.xx | xx.x | xx.xx |
Previous Stories
Dr Boreham’s Crucible: Neuren Pharmaceuticals
Mar 11 2024
Tim Boreham reports Neuren Pharmaceuticals has suffered from accusations from an activist shorter which others have debunked
Spotlight On ASX-Listed Cannabis Companies
Jan 31 2024
Some cannabis gems are sprouting in the ASX weed patch, but they are hard to find in the haze of hype, Tim Boreham, Editor, The New Criterion reports
Transformational Trial Results For Neuren Pharmaceuticals
Dec 20 2023
Brokers raise valuations for Neuren Pharmaceuticals following positive Phase 2 clinical trial results
Dr Boreham’s Crucible: Imugene
Dec 11 2023
Tim Boreham highlights the prospects for cancer treatment biotech Imugene
Dr Boreham’s Crucible: PYC Therapeutics
Nov 22 2023
Tim Boreham highlights how PYC Therapeutics’ gene therapy can address a plethora of genetic afflictions
Dr Boreham’s Crucible: Paradigm Biopharmaceuticals
Nov 06 2023
Tim Boreham highlights the success of Paradigm Biopharmaceuticals’ joint pain drug ahead of a capital raising
Dr Boreham’s Crucible: Argenica Therapeutics
Sep 28 2023
Argenica Therapeutics is aiming for a substantial slice of the stroke market, expected to be worth some US$180bn a year by 2030
Dr Boreham’s Crucible: Cleo Diagnostics
Aug 30 2023
Tim Boreham shines a light on freshly listed Cleo Diagnostics, in search of an effective diagnostic tool for ovarian cancer
Breaking Boundaries: Medical Psychedelics
Aug 21 2023
Australia is the first country in the world to legalise the use of psychedelic drugs for mental illness
Momentum Keeps Building For Avita Medical
Aug 15 2023
Brokers raise target prices for Avita Medical following second quarter results amidst anticipation of exciting prospects in the outlook period
Latest News
1 |
Today’s Financial Calendar – 25-04-2024Apr 25 2024 - Daily Market Reports |
2 |
ASX Winners And Losers Of Today – 24-04-24Apr 24 2024 - Daily Market Reports |
3 |
Australian Broker Call *Extra* Edition – Apr 24, 2024Apr 24 2024 - Daily Market Reports |
4 |
Brambles’ Divisive March QuarterApr 24 2024 - Australia |
5 |
Orora Awaiting The End Of DestockingApr 24 2024 - Australia |